Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
05/2002
05/07/2002US6384188 Lipopolysaccharide-binding and neutralizing peptides
05/07/2002US6384080 Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase
05/07/2002US6384077 Highly purified EPA for treatment of schizophrenia and related disorders
05/07/2002US6384072 Carbamyl substituted compounds with ether groups
05/07/2002US6384070 Restenosis, kidney diseases, lung diseases
05/07/2002US6384069 Brain disorders chronic pain, hypoglycemia, hypoxia, trauma, alzheimer's disease, aids-associated dementia, amyotrophic lateral sclerosis, parkinson's disease, and chronic alcoholism, comprising administering to a patient in need a
05/07/2002US6384047 Breathing disorders and hypotensive agents
05/07/2002US6384046 Treating neointimal proliferation and thickening
05/07/2002US6384029 Optically active pyridyl-4h-1,2,4-oxdadiazine derivative and its use in the treatment of vascular diseases
05/07/2002US6384024 Bile salt conjugates
05/07/2002US6384022 Enzyme inhibitors
05/07/2002US6384021 Heparin compositions of very low molecular weight
05/07/2002US6383808 Antisense inhibition of clusterin expression
05/07/2002US6383790 Pyrazolo(3,4-d)pyrimidine based compound; anticarcinogenic agents; antitumor agents
05/07/2002US6383780 2786, a novel human aminopeptidase
05/07/2002US6383528 Antithrombotic preparation to suppress neutropenia, agranulocytosis, ischemia, and other side effects from the use of ticlopidine alone;
05/07/2002US6383484 Antibodies to truncated VEGF-D and thereof
05/07/2002CA2348845A1 Adenosine as antithrombotic
05/07/2002CA2216535C Protein kinase c inhibitors
05/07/2002CA2145000C Compounds which are selective antagonists of the human nk3 receptor and their use as medicinal products and diagnostic tools
05/05/2002WO2002042270A1 Substituted benzene derivatives or salts thereof
05/02/2002WO2002035235A2 Net as regulator of angiogenic expression
05/02/2002WO2002034941A1 Method for screening active molecules for treating and preventing atherosclerotic lesions and its uses
05/02/2002WO2002034940A2 Methods for screening compounds that modulate lipid metabolism
05/02/2002WO2002034904A1 Novel g protein-coupled receptor protein and dna thereof
05/02/2002WO2002034783A2 Transmembrane proteins
05/02/2002WO2002034781A1 Human g-protein coupled diadenosine tetraphosphate receptor (ap4ar)
05/02/2002WO2002034767A1 Vegf peptides and their use for inhibiting angiogenesis
05/02/2002WO2002034761A1 Pyranoside derivatives
05/02/2002WO2002034753A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
05/02/2002WO2002034747A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
05/02/2002WO2002034741A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
05/02/2002WO2002034726A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
05/02/2002WO2002034721A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors
05/02/2002WO2002034718A1 Amide derivatives as nmda receptor antagonists
05/02/2002WO2002034716A2 Pyrrolidine modulators of ccr5 chemokine receptor activity
05/02/2002WO2002034705A2 C-nitroso compounds and use thereof
05/02/2002WO2002034303A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency
05/02/2002WO2002034285A2 Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
05/02/2002WO2002034283A2 Vegh inhibitors and their use
05/02/2002WO2002034279A1 Oral preparation containing seaweed for reduction of plaque and calculus
05/02/2002WO2002034277A1 Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara
05/02/2002WO2002034273A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders
05/02/2002WO2002034263A1 Preventives/remedies for portal hypertension
05/02/2002WO2002034262A1 Combination of catechin and quercetin for pharmaceutical or dietary use
05/02/2002WO2002034259A1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction
05/02/2002WO2002034252A1 Drug composition comprising dipeptydyl aldehyde derivative
05/02/2002WO2002034250A1 Fat emulsions
05/02/2002WO2002034248A2 METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION
05/02/2002WO2002034243A2 Method for the treatment of neurological and neuropsychological disorders
05/02/2002WO2002034242A2 Method for the treatment of neurological and neuropsychological disorders
05/02/2002WO2002034236A2 Lipid formulations for target delivery
05/02/2002WO2002034202A2 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
05/02/2002WO2002011710A3 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
05/02/2002WO2002002103A3 Compositions based on aminoacids, suitable for the treatment of heart failure
05/02/2002WO2001098361A3 Agonist anti-trk-c monoclonal antibodies
05/02/2002WO2001098330A3 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS
05/02/2002WO2001096397A3 Cd154 variants and uses thereof
05/02/2002WO2001090074A3 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a)
05/02/2002WO2001082913A3 Use of benzamide derivatives for the treatment of high ocular tension and glaucoma
05/02/2002WO2001081298A3 Cyclic carboxylic acids as integrin antagonists
05/02/2002WO2001077137A9 Albumin fusion proteins
05/02/2002WO2001074900A3 Nuclear factor kb inducing factor
05/02/2002WO2001072778A3 Method of identifying inhibitors of tie-2
05/02/2002WO2001070771A3 Acute neuronal induced calcium binding protein type 1 ligand
05/02/2002WO2001070733A3 Di-substituted iminoheterocyclic compounds
05/02/2002WO2001066772A3 Heparinase iii and uses thereof
05/02/2002WO2001062923A3 Transporters and ion channels
05/02/2002WO2001061009A3 Polypeptides and nucleic acids encoding same
05/02/2002WO2001061008A3 Polypeptides and nucleic acids encoding same
05/02/2002WO2001055210A3 Human cyr61
05/02/2002WO2001054686A3 L-arginine in combination with other compounds for treating cardiovascular diseases
05/02/2002WO2001046394A3 Mammalian protein phosphatases
05/02/2002WO2001044264A3 Novel stromelysin inhibitors
05/02/2002WO2001043757A3 Composition comprising ingredients of panax ginseng and ginko biloba
05/02/2002WO2001036979A3 Placental human neurokinin b precursor
05/02/2002WO2001024828A3 MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN αVβ3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
05/02/2002WO2001023375A3 Substituted pyridines and pyridazines with angiogenesis inhibiting activity
05/02/2002WO2001022949A3 Use of alprostadil (prostaglandin e1) for producing a medicament for angioneogenesis
05/02/2002WO2001018172A3 Fibroblast growth factor-like polypeptides
05/02/2002WO2001009121A3 2-pyrazolin-5-ones_as tyrosine kinase inhibitors
05/02/2002WO2000078972A3 Regulation with binding cassette transporter protein abc1
05/02/2002US20020052530 Such as 3-(N-1-indanylamino)-indan-1-one 3-(N-1-indanylamino) indan-1-one formed by reacting amino-indane compound with bromo-indanone compound in presence of triethyleneamine
05/02/2002US20020052512 Diaminopropionic acid derivatives
05/02/2002US20020052495 Pyramidine or triazine derivatives which specifically inhibit the binding of endothelin to the receptor
05/02/2002US20020052443 Non-antigenic branched polymer conjugates
05/02/2002US20020052407 Modulating expression, production, or formation of amyloid precursor protein by administering a nonsteroidal antiinflammatory agent that is a cyclooxygenase inhibitor
05/02/2002US20020052404 Compositions and methods for treating or preventing diseases of body passageways
05/02/2002US20020052400 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors.
05/02/2002US20020052398 Pharmaceutical composition of 6-amino EM-12
05/02/2002US20020052397 Treatment of diseases characterized by excess Th2 cytokines and/ or an excess IgE production.
05/02/2002US20020052392 Have utility as, inter alia, hypoglycemic, and anti-obesity agents.
05/02/2002US20020052391 Tetrahydroquinoline derivatives as glycine antagonists
05/02/2002US20020052388 Treatment method
05/02/2002US20020052387 5-Substituted 2-aryl-4-pyrimidinones
05/02/2002US20020052386 Pyrimidine derivatives
05/02/2002US20020052383 Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity.
05/02/2002US20020052377 Method for treating angina
05/02/2002US20020052371 Neuropeptide Y receptor antagonist; treatment of bulimia, obesity or diabetes; e.g., spiro(isobenzofuran-1-(3H),4'-pyridine)-1'-carboxamides
05/02/2002US20020052369 Indolinone derivatives as protein kinase/phosphatase inhibitors
1 ... 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 ... 1595